Catherine Ju-Ying Wu, M.D.
Title Professor of Medicine Institution Dana-Farber Cancer Institute Address Dana-Farber Cancer Institute
Medical Oncology, Dana 520C
450 Brookline Ave
Boston MA 02215
|
|
Mentoring
Investigation of Epitope Spreading and the T Cell Repertoire Following a Personalized Neoantigen Vaccine
Full Time/Year Long, 01/09/17 - 12/20/17
Establishing a pipeline to discover the T cell repertoire after neoantigen vaccine using paired TCRαβ chain single cell sequencing
Summer, 06/01/15 - 08/19/15
Effective Graft-Versus-Leukemia Responses Are Associated with Nucleic Acid-Immunoglobulin Complexes that Stimulate TLR8 and TLR9
Summer, 06/05/07 - 08/25/07
Genomic Basis for Resistance to BCL2 Inhibition in Hematologic Malignancies
Full Time, 05/30/16 - 09/02/16
Research
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
Faculty can
login
to make corrections and additions.
-
R01CA276865
(CHEN, FEI)
Feb 1, 2023 - Jan 31, 2028
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
Role: Co-Principal Investigator
-
R01HL157174
(KESKIN, DERIN B)
Apr 1, 2022 - Mar 31, 2026
Systematic identification of minor histocompatibility antigens to address GVHD
Role: Co-Principal Investigator
-
R21CA267527
(WU, CATHERINE JU-YING)
Feb 1, 2022 - Jan 31, 2024
Defining the impact of mutational drivers on the immune microenvironment of CLL
Role: Principal Investigator
-
U24CA224331
(WU, CATHERINE JU-YING)
Sep 30, 2017 - Jun 30, 2028
Cancer Immune Monitoring and Analysis Center
Role: Principal Investigator
-
R21CA220147
(KHARCHENKO, PETER V)
Aug 1, 2017 - Jul 31, 2021
Single-cell analysis of tumor-microenvironment interactions in follicular lymphoma
Role: Co-Principal Investigator
-
R01CA216273
(WU, CATHERINE JU-YING)
May 11, 2017 - Apr 30, 2022
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
Role: Principal Investigator
-
P01CA206978
(WU, CATHERINE JU-YING)
Sep 1, 2016 - Aug 31, 2026
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes
Role: Principal Investigator
-
R01CA184922
(WU, CATHERINE JU-YING)
Jun 1, 2014 - May 31, 2018
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
Role: Principal Investigator
-
R01CA182461
(WU, CATHERINE JU-YING)
Dec 19, 2013 - Nov 30, 2018
Defining the impact of clonal evolution on chronic lymphocytic leukemia
Role: Principal Investigator
-
R01HL116452
(WU, CATHERINE JU-YING)
Feb 1, 2013 - Jan 31, 2018
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia
Role: Principal Investigator
-
R01CA155010
(WU, CATHERINE JU-YING)
Dec 1, 2010 - Jan 31, 2027
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Role: Principal Investigator
-
R01HL103532
(WU, CATHERINE JU-YING)
Jun 1, 2010 - May 31, 2014
Post-transplant vaccines to enhance graft-versus-leukemia responses
Role: Principal Investigator
-
R21CA132232
(WU, CATHERINE JU-YING)
Apr 1, 2008 - Mar 31, 2010
GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity
Role: Principal Investigator
-
R21CA115043
(WU, CATHERINE JU-YING)
Jun 1, 2005 - May 31, 2007
GM - CSF - producing tumor cell line as a CML vaccine
Role: Principal Investigator
-
K08HL004293
(WU, CATHERINE JU-YING)
Sep 1, 2000 - Aug 31, 2005
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION
Role: Principal Investigator
Bibliographic
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.